Table 3.
Univariate and multivariate analyses for prognostic factors of DFS after curative resection for stage I‐III RCC and LCRC
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| RCC | ||||||
| Age (≥64 vs <64 y) | 1.36 | 0.75‐2.48 | .315 | |||
| Gender (male vs female) | 1.21 | 0.66‐2.19 | .540 | |||
| T stage (T3‐4 vs T1‐2) | 3.48 | 1.08‐11.25 | .037 | 2.07 | 0.62‐6.88 | .235 |
| N stage (N1‐2 vs N0) | 2.16 | 1.17‐3.96 | .013 | 1.98 | 1.09‐3.60 | .036 |
| Differentiation (poor vs others) | 2.31 | 1.27‐4.18 | .006 | 2.02 | 1.10‐3.72 | .024 |
| Lymphovascular invasion | 2.51 | 1.34‐4.69 | .004 | 2.09 | 1.07‐4.10 | .031 |
| Perineural invasion | 1.63 | 0.82‐3.23 | .163 | |||
| No. of lymph node (≥12 vs <12) | 1.33 | 0.59‐2.98 | .495 | |||
| CEA(≥4.25 ng/mL vs <4.25 ng/mL) | 2.07 | 1.12‐3.83 | .021 | 1.95 | 1.02‐3.72 | .044 |
| NLR (≥2.3 vs <2.3) | 2.14 | 1.08‐4.24 | .029 | 2.32 | 1.15‐4.66 | .018 |
| PLR (≥145.2 vs <145.2) | 2.31 | 1.11‐4.81 | .025 | 2.43 | 1.09‐5.42 | .030 |
| LMR (<3.5 vs ≥3.5) | 2.25 | 1.18‐4.31 | .014 | 2.16 | 1.11‐4.20 | .024 |
| LCRC | ||||||
| Age (≥64 vs <64 y) | 1.47 | 0.85‐2.55 | .171 | |||
| Gender (male vs female) | 1.49 | 0.82‐2.69 | .187 | |||
| T stage (T3‐4 vs T1‐2) | 5.42 | 1.69‐17.40 | .005 | 5.16 | 1.58‐16.82 | .007 |
| N stage (N1‐2 vs N0) | 1.96 | 1.13‐3.41 | .017 | 1.85 | 1.06‐3.23 | .031 |
| Differentiation (poor vs others) | 2.94 | 1.67‐5.20 | <.001 | 1.96 | 1.07‐3.60 | .030 |
| Lymphovascular invasion | 3.34 | 1.89‐5.91 | <.001 | 3.54 | 1.92‐6.52 | <.001 |
| Perineural invasion | 1.37 | 0.72‐2.62 | .343 | |||
| No. of lymph node (≥12 vs <12) | 1.40 | 0.73‐2.68 | .310 | |||
| CEA(≥4.25 ng/mL vs <4.25 ng/mL) | 1.90 | 1.08‐3.34 | .025 | 2.45 | 1.35‐4.45 | .003 |
| NLR (≥2.3 vs <2.3) | 2.08 | 1.19‐3.63 | .010 | 1.60 | 0.89‐2.87 | .115 |
| PLR (≥145.2 vs <145.2) | 2.28 | 1.31‐3.97 | .004 | 2.84 | 1.57‐5.15 | .001 |
| LMR (<3.5 vs ≥3.5) | 1.58 | 0.91‐2.74 | .104 | |||
Abbreviations: 95%CI, 95% confidential interval; CEA, carcinoembryonic antigen; DFS, disease‐free survival; HR, hazard ratio; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; RCRC, right‐sided colon cancer.